Keywords: Abbott, Trilipix and statins, FDA advisory, dislipedemia, Cholesterol

FDA advisory panel backs continued use of Abbott’s Trilipix with statins

Article | 20 May 2011

Print This

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in